Spero Therapeutics (NASDAQ:SPRO) and Puma Biotechnology (NASDAQ:PBYI) Head-To-Head Comparison
Spero Therapeutics (NASDAQ:SPRO) and Puma Biotechnology (NASDAQ:PBYI) Head-To-Head Comparison
Spero Therapeutics (NASDAQ:SPRO – Get Rating) and Puma Biotechnology (NASDAQ:PBYI – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, earnings, analyst recommendations and dividends.
纳斯达克(SproGet Rating)和彪马生物科技(Puma Biotech)(纳斯达克：PBYI-GET Rating)都是小盘医疗公司，但哪只股票更好？我们将根据两家公司的机构所有权、风险、估值、盈利能力、收益、分析师建议和股息来比较它们的实力。
Profitability
盈利能力
This table compares Spero Therapeutics and Puma Biotechnology's net margins, return on equity and return on assets.
此表比较了Spero治疗公司和彪马生物技术公司的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Spero Therapeutics | -1,162.35% | -186.94% | -92.07% |
| Puma Biotechnology | 4.50% | 84.14% | 4.78% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| Spero治疗公司 | -1,162.35% | -186.94% | -92.07% |
| 彪马生物技术 | 4.50% | 84.14% | 4.78% |
Valuation and Earnings
估值和收益
This table compares Spero Therapeutics and Puma Biotechnology's top-line revenue, earnings per share (EPS) and valuation.
此表比较了Spero治疗公司和彪马生物技术公司的营收、每股收益(EPS)和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Spero Therapeutics | $18.26 million | 3.63 | -$89.76 million | ($3.11) | -0.61 |
| Puma Biotechnology | $253.20 million | 0.79 | -$29.13 million | $0.22 | 20.05 |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| Spero治疗公司 | 1,826万美元 | 3.63 | -8,976万美元 | ($3.11) | -0.61 |
| 彪马生物技术 | 2.532亿美元 | 0.79 | -2,913万元 | $0.22 | 20.05 |
Analyst Ratings
分析师评级
This is a breakdown of recent ratings and recommmendations for Spero Therapeutics and Puma Biotechnology, as reported by MarketBeat.com.
这是MarketBeat.com报道的Spero治疗公司和彪马生物技术公司最近的评级和推荐细目。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Spero Therapeutics | 0 | 2 | 2 | 0 | 2.50 |
| Puma Biotechnology | 0 | 0 | 1 | 0 | 3.00 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| Spero治疗公司 | 0 | 2 | 2 | 0 | 2.50 |
| 彪马生物技术 | 0 | 0 | 1 | 0 | 3.00 |
Spero Therapeutics presently has a consensus price target of $6.33, suggesting a potential upside of 235.10%. Puma Biotechnology has a consensus price target of $8.00, suggesting a potential upside of 81.41%. Given Spero Therapeutics' higher probable upside, research analysts plainly believe Spero Therapeutics is more favorable than Puma Biotechnology.
Spero治疗公司目前的共识目标价为6.33美元，这意味着潜在的上涨235.10%。彪马生物技术的共识目标价为8.00美元，暗示潜在上涨81.41%。鉴于Spero治疗公司更有可能上行，研究分析师显然认为Spero治疗公司比彪马生物技术公司更有利。
Insider & Institutional Ownership
内部人与机构所有权
57.4% of Spero Therapeutics shares are held by institutional investors. Comparatively, 60.6% of Puma Biotechnology shares are held by institutional investors. 4.4% of Spero Therapeutics shares are held by company insiders. Comparatively, 21.2% of Puma Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Spero治疗公司57.4%的股份由机构投资者持有。相比之下，彪马生物技术公司60.6%的股份由机构投资者持有。Spero Treateutics 4.4%的股份由公司内部人士持有。相比之下，彪马生物技术公司21.2%的股份由公司内部人士持有。强大的机构持股表明，大型基金管理公司、对冲基金和捐赠基金相信，一家公司有望实现长期增长。
Risk and Volatility
风险和波动性
Spero Therapeutics has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500.
Spero Treateutics的贝塔系数为0.79，这表明其股价的波动性比标准普尔500指数低21%。相比之下，彪马生物科技的贝塔系数为0.91，这表明其股价的波动性比标准普尔500指数低9%。
Summary
摘要
Puma Biotechnology beats Spero Therapeutics on 11 of the 14 factors compared between the two stocks.
彪马生物技术在两只股票比较的14个因素中有11个击败了Spero治疗公司。
About Spero Therapeutics
关于Spero治疗公司
(Get Rating)
(获取评级)
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Spero治疗公司是一家临床阶段的生物制药公司，专注于在美国识别、开发和商业化多药耐药(MDR)细菌感染和罕见疾病的治疗方法。该公司的候选产品包括口服碳青霉烯类抗生素氢溴酸替比培南(HBR)，用于治疗复杂的尿路感染，包括成人肾盂肾炎；SPR206，一种直接作用的静脉给药，用于治疗医院内的多药耐药革兰氏阴性细菌感染；以及SPR720，一种用于治疗非结核分枝杆菌肺部疾病的口服抗生素。它与明治精工制药株式会社签署了支持特比培南HBR开发的许可协议；与珠峰制药签署了在大中国、韩国和东南亚国家开发、生产和商业化SPR206的许可协议；与比尔和梅琳达·盖茨医学研究所签署了合作协议，开发用于治疗结核分枝杆菌引起的肺部感染的SPR720；与Vertex PharmPharmticals Inc.签署了与SPR720以及活性代谢物SPR719相关的专利许可协议。该公司成立于2013年，总部位于马萨诸塞州剑桥市。
About Puma Biotechnology
关于彪马生物技术
(Get Rating)
(获取评级)
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
彪马生物技术公司是一家生物制药公司，专注于产品的开发和商业化，以加强美国和国际上的癌症护理。该公司的候选药物包括用于HER2过度表达/放大的早期乳腺癌患者的PB272 neratinib(口服)；用于将neratinib与卡培他滨结合用于治疗晚期或转移性HER2阳性乳腺癌的成年患者的PB272(neratinib，口服)；用于HER2突变阳性实体肿瘤的PB272(neratinib，口服)。它与辉瑞公司签订了许可协议，与专业治疗亚洲有限公司、北海康成制药生物医疗有限公司、品特制药国际公司、奈特治疗公司、皮埃尔·法布雷药物公司和Bixink治疗有限公司签订了分许可协议。该公司成立于2010年，总部设在加利福尼亚州洛杉矶。
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Spero治疗日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Spero治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。